Clinical Trial Update: A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II trial evaluating bevacizumab with bortezomib in relapsed/refractory multiple myeloma; study terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Bortezomib (bortezomib)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2022-07-20